Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cellular Injury IlI: Cellular Death01:11

Cellular Injury IlI: Cellular Death

Cell death is the irreversible loss of cellular structure and function, representing the final stage of severe injury. It plays a key role in both normal physiology and disease.Types of Cell DeathThe two main types are necrosis and apoptosis, though others like necroptosis and pyroptosis also exist.Necrosis:Necrosis is an unregulated form of cell death caused by severe injury such as trauma, toxins, or ischemia. It is characterized by cell swelling, membrane loss, rupture, and leakage of...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Phagocytosis of Apoptotic Cells01:17

Phagocytosis of Apoptotic Cells

Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or  immature dendritic cells. Non-professional phagocytes such as  epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes. 
Normal cells contain receptors that prevent them from being recognized by phagocytes.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introducing the need for a consensus-based framework for protocol modifications to improve trial trustworthiness.

BMC medicine·2026
Same author

Correction: Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy.

The Journal of experimental medicine·2026
Same author

Therapie·2026
Same author

How can the level of health product education (literacy) be raised among the general public?

Therapie·2026
Same author

Reusing clinical trial data to consolidate and advance medical knowledge.

Journal of clinical epidemiology·2025
Same author

Rapid-sequence clinical research before and during a pandemic: Lessons learned and the way forward.

Infectious diseases now·2025
Same journal

Multiomics Profiling During Autoimmune Demyelination Highlights a Complex Regulatory Role for Ataxin-1 in B Cells.

Annals of the New York Academy of Sciences·2026
Same journal

Global Trends in Light Pollution and Their Relationship With Socioeconomic Factors.

Annals of the New York Academy of Sciences·2026
Same journal

Wired for Corruption: Inter-Brain Synchrony Encodes Bribery-Related Value Information and Predicts Bribery Agreement.

Annals of the New York Academy of Sciences·2026
Same journal

LM-YOLO: A Lightweight Multi-Scale Enhanced Model for Forest Smoke Detection Using Unmanned Aerial Vehicles.

Annals of the New York Academy of Sciences·2026
Same journal

Polyrhythm Perception and Production: A Scoping Review.

Annals of the New York Academy of Sciences·2026
Same journal

DARTS-CNN-BiLSTM: Intelligent Fault Diagnosis for Computer Numerical Control Machine Tool Feed System.

Annals of the New York Academy of Sciences·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Desirable cell death during anticancer chemotherapy.

Clara Locher1, Rosa Conforti, Laetitia Aymeric

  • 1Institut National de la Santé et de la Recherche Médicale, U1015, Villejuif, France.

Annals of the New York Academy of Sciences
|October 21, 2010
PubMed
Summary
This summary is machine-generated.

Immunogenic chemotherapy uses cell death to activate T cells against tumors, enhancing treatment efficacy. This review explores tumor changes and immune adjuvants to improve chemotherapy

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer
08:26

Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer

Published on: March 24, 2013

Related Experiment Videos

Last Updated: Jun 7, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer
08:26

Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer

Published on: March 24, 2013

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Emerging concept of immunogenic chemotherapy leverages cytotoxic drugs to induce specific cell death.
  • This cell death can trigger anti-tumor T cell responses, improving treatment and preventing relapse.
  • Most current chemotherapy drugs induce non-immunogenic apoptosis, lacking therapeutic immune stimulation.

Purpose of the Study:

  • To discuss molecular and metabolic alterations in tumors necessary for immunogenic cell death.
  • To identify host pathways critical for inducing protective T cell responses during chemotherapy.
  • To review immune adjuvants that enhance chemotherapy's immunogenicity and efficacy.

Main Methods:

  • Review of existing literature on chemotherapy-induced cell death and anti-tumor immunity.
  • Analysis of molecular and metabolic pathways involved in immunogenic cell death.
  • Examination of immune adjuvants and their mechanisms in augmenting chemotherapy.

Main Results:

  • Specific cell-death modalities are crucial for eliciting cross-priming of tumor antigen-specific T cells.
  • Tumor molecular/metabolic changes and host immune pathways interplay to induce protective Tc1 responses.
  • Immune adjuvants show potential in boosting chemotherapy-induced immunogenicity.

Conclusions:

  • Harnessing immunogenic chemotherapy requires understanding tumor cell death and host immune interactions.
  • Targeting specific molecular and metabolic pathways can enhance chemotherapy's anti-tumor immune effects.
  • Further research into immune adjuvants can optimize immunogenic chemotherapy strategies.